BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,300.00
- Market cap
- ₹64,912 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.1×Sector 46.5×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Other board meeting date announcements
All →Jetking Infotrain Board Meeting Date
Jetking Infotrain has scheduled a board meeting on November 4, 2026 to consider unaudited quarterly and half-year results. The trading window remains closed until 48 hours after the results announcement.
Metropolis Healthcare Board Meeting Date
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Aelea Commodities Board Meeting Date
Aelea Commodities has scheduled a board meeting for 2 November 2026 to consider half-year results and other items. The agenda includes an additional independent director, a director resignation, and business expansion and capex.
R Systems International Board Meeting Date
R Systems International will hold a board meeting on 3 November 2026 to consider quarterly and nine-month results to September 2026. The trading window remains closed until 48 hours after the results are declared.
Onida Electronics Board Meeting Date
Onida Electronics schedules a 3 November 2026 board meeting for Q2 and half-year results and ESOP share allotment. Trading window stays closed until 48 hours post-results.
Platinum Industries Board Meeting Date
Platinum Industries Ltd intimated a board meeting on November 4, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window closed from October 1, 2026.